Amicus Therapeutics, a global biotechnology company focused on discovering, developing, and delivering novel medicines for rare metabolic diseases, announced regulatory and clinical advancements in its development program AT-GAA for Pompe disease. During the third quarter, Amicus held a Type C meeting with the United States Food and Drug Administration (FDA) in order to discuss the regulatory path…